reality. From July 2012 until October 2013 we closely followed the decision making process. We attended hearings where everybody had the opportunity to try to convince the CVZ to change its views.
The CVZ refused to withdraw its proposal, but finally made a U-turn and advised the Minister to maintain the reimbursement of the therapies for all patients. The patients and their relatives were relieved. One could argue that common decency won.
But the real problem remains unsolved. Why are these enzyme-therapies so expensive? Why are they so mediocre? Is it true that the industry lacks incentives to come up with a better product since the limited one generates such a substantial amount of money?
